OUP

Quintessent raises $11.5M in seed funding to future-proof optical connectivity

Retrieved on: 
Thursday, March 14, 2024
Software, Technology, Artificial Intelligence, Data Management, A.I, Partner, Sierra Ventures, OUP, Merck Group, Growth, Silicon, Cryptocurrency

Quintessent, a pioneer in heterogeneous silicon photonics and quantum dot laser technology, has closed on just over $11.5 million in an oversubscribed Seed funding round.

Key Points: 
  • Quintessent, a pioneer in heterogeneous silicon photonics and quantum dot laser technology, has closed on just over $11.5 million in an oversubscribed Seed funding round.
  • Osage University Partners (OUP) led the round along with new investors including M Ventures, and joining existing investors Sierra Ventures, Foothill Ventures, and Entrada Ventures.
  • is catalyzing a rapid transition and growth of the world’s computing infrastructure from general purpose architectures to ones specifically designed for accelerated computing.
  • As a result, data movement efficiency of the interconnecting fabric is a critical bottleneck to accelerating system performance at scale.

Q32 Bio and Homology Medicines Announce Merger Agreement

Retrieved on: 
Thursday, November 16, 2023
Bristol Myers Squibb, ANCA, AA, Clinical trial, Patient, Alopecia areata, Atopic dermatitis, Therapy, Q32, OrbiMed, Trial of the century, TSLP, IL-7, System, Autoimmunity, AAV, OUP, Vaccine, Pharmaceutical industry

WALTHAM, Mass. and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases. Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.

Key Points: 
  • and BEDFORD, Mass., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, and Homology Medicines, Inc. (Nasdaq: FIXX), today announced they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
  • The combined company will focus on advancing Q32 Bio’s wholly owned clinical development candidates for the treatment of autoimmune and inflammatory diseases.
  • Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under the Nasdaq ticker symbol “QTTB”.
  • “The proposed merger with Homology Medicines and concurrent private placement is expected to provide Q32 Bio with the capital to drive development of our autoimmune and inflammatory pipeline through multiple clinical milestones,” said Jodie Morrison, Chief Executive Officer of Q32 Bio.

OUPES Introduces Mega 2 Portable Power Station: The Ultimate Off-Grid Solution for RV Living

Retrieved on: 
Wednesday, November 15, 2023
Sale, Microwave, Recreational vehicle, EPS, AC, OUP, Power Station, Renewable energy, Electric motor, RV

Designed specifically for RV off-grid living, this state-of-the-art power station offers unmatched performance, reliability, and convenience.

Key Points: 
  • Designed specifically for RV off-grid living, this state-of-the-art power station offers unmatched performance, reliability, and convenience.
  • With a maximum AC charging power of 1600W and solar charging power of 2100W, you can replenish the power station in record time.
  • With the launch of the Mega2 Power Station, OUPES is revolutionizing off-grid living for RV enthusiasts and outdoor adventurers alike.
  • For more information about OUPES and their range of portable solar power solutions, please visit www.oupes.com .

Verve Motion Raises $20 Million in Series B Financing

Retrieved on: 
Wednesday, December 13, 2023
Pillar, Harvard University, Back injury, Research, Albertsons, Safety, Injury, Entrepreneurship, DARPA, National Science Foundation, Applied science, Investment, Risk, SolidWorks, Fatigue, Automation, Venture round, Powered exoskeleton, Health, Software, Partnership, Occupational safety and health, Iran National Science Foundation, Growth, Bangladesh Technical Education Board, Military personnel, Workplace, Robotics, OUP, Personal protective equipment, Onshape, Okta, Series, Engineering

CAMBRIDGE, Mass., Dec. 13, 2023 /PRNewswire/ -- Pioneering the future of industrial safety, Verve Motion, a Harvard University spinout, today announced it has reached a significant milestone by securing $20 million in Series B funding. This achievement, raising the company's total funding to over $40 million, marks a crucial step in the company's rapid expansion and the widespread adoption of its innovative industrial-use connected wearable technology, SafeLift™ exosuit.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 13, 2023 /PRNewswire/ -- Pioneering the future of industrial safety, Verve Motion, a Harvard University spinout, today announced it has reached a significant milestone by securing $20 million in Series B funding.
  • Occupational back pain ranks as the most frequent injury, with more than one million workers suffering back injuries annually.
  • "The era of transformation in workplace safety and productivity is here," said Ignacio Galiana, the CEO and Co-founder of Verve Motion.
  • "As a lead investor in the Series B funding, we are excited to fuel the growth and innovation of Verve Motion, a trailblazing force in wearable robotics," said Arunas Chesonis, co-founder of Safar Partners.

Wolters Kluwer collaborates with German publishing company C.H.Beck

Retrieved on: 
Monday, November 13, 2023
Research, University of Oxford, IP, Breast International Group, AAA, American Arbitration Association, International Marxist Group, Wolters Kluwer, Oxford University Press, OUP, Practice of law

NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced a new collaboration with the German publishing company C.H.Beck. Kluwer Arbitration and Kluwer IP Law subscribers can now gain integrated access to key titles from C.H.Beck, and have easy access to the most complete and valuable analysis in arbitration and IP law.

Key Points: 
  • NEW YORK, Nov. 13, 2023 /PRNewswire/ -- Wolters Kluwer Legal & Regulatory U.S. today announced a new collaboration with the German publishing company C.H.Beck.
  • Kluwer Arbitration and Kluwer IP Law subscribers can now gain integrated access to key titles from C.H.Beck, and have easy access to the most complete and valuable analysis in arbitration and IP law.
  • Kluwer Arbitration and Kluwer IP Law customers will now have access to nine well-respected titles offering immediate and practical value.
  • Wolters Kluwer also recently extended its collaborations with both Oxford University Press (OUP) and the American Arbitration Association (AAA), licensing a selection of key titles published by OUP and AAA for Kluwer Arbitration, Kluwer Competition Law , and Kluwer IP Law.

OUPES Introduces Mega 2 Portable Power Station: The Ultimate Off-Grid Solution for RV Living

Retrieved on: 
Friday, November 3, 2023
Power Station, Sale, Microwave, OUP, AC, EPS, Mega2, the Manipulation Environment for Genetic Analysis, Recreational vehicle, Renewable energy, Electric motor, RV

Designed specifically for RV off-grid living, this state-of-the-art power station offers unmatched performance, reliability, and convenience.

Key Points: 
  • Designed specifically for RV off-grid living, this state-of-the-art power station offers unmatched performance, reliability, and convenience.
  • With a maximum AC charging power of 1600W and solar charging power of 2100W, you can replenish the power station in record time.
  • With the launch of the Mega2 Power Station, OUPES is revolutionizing off-grid living for RV enthusiasts and outdoor adventurers alike.
  • For more information about OUPES and their range of portable solar power solutions, please visit www.oupes.com

ReCode Therapeutics Announces Closing of Extension to Series B Financing

Retrieved on: 
Tuesday, September 19, 2023
Biotechnology, Pharmaceutical, Genetics, Health, Tissue, Central nervous system, Therapy, Doctor of Philosophy, SORT, BLV, MBA, Recode, Cell, Messenger, OUP, Lung, Bayer, Kouki, OrbiMed, Andreessen Horowitz, Investment, Patient, Cystic fibrosis, Drug discovery, Liver, LNP, Primary ciliary dyskinesia, Vaccine, Pharmaceutical industry

ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.

Key Points: 
  • ReCode Therapeutics , a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics, today announced the closing of an extension to its Series B financing, raising an additional $50 million, and the appointment of Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), to the company’s board of directors.
  • The company recently concluded a final extension to its Series B financing, raising an additional $50 million, for a total of $260 million in funding.
  • At BLV, we focus on funding next-generation therapeutics platforms and developing first- and best-in-class programs.
  • ReCode, with its cutting-edge genetic medicine platform, is well aligned with our mission,” said Dr. Harasaki.

USRA to administer Integrative Research in Emerging Technologies for Department of Homeland Security Use Cases Program

Retrieved on: 
Wednesday, January 25, 2023
UAS, Disaster, Artificial intelligence, HSI, Universities Space Research Association, Historically black colleges and universities, OUP, RIACS, University, Student, USRA, Research Institute for Advanced Computer Science, Partnership, DHS, Faculty, Minority-serving institution, MSRDC, Research, STEM, Aircraft, International Disability and Development Consortium, Education, MSI, Nintendo Integrated Research & Development, Management

WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- Through a new agreement with the MSI STEM Research & Development Consortium (MSRDC), the Universities Space Research Association (USRA) will administer the Integrative Research in Emerging Technologies for Department of Homeland Security (DHS) Use Cases Program.

Key Points: 
  • WASHINGTON, Jan. 25, 2023 /PRNewswire/ -- Through a new agreement with the MSI STEM Research & Development Consortium (MSRDC), the Universities Space Research Association (USRA) will administer the Integrative Research in Emerging Technologies for Department of Homeland Security (DHS) Use Cases Program.
  • This new program is designed to enable innovation in emerging technologies for DHS use cases, through an integrated portfolio of use-inspired and foundational research for emerging technologies including artificial intelligence (AI), quantum information science (QIS), and autonomous & unmanned aircraft systems (UAS).
  • "This program will drive innovation with an integrated portfolio of use-inspired and foundational research in emerging technologies focused on supporting high priority needs of today while preparing for the future at the same time" says Dr. David Bell, Principal Investigator of the Integrative Research in Emerging Technologies for DHS Use Cases Program and Director of the USRA Research Institute for Advanced Computer Science (RIACS).
  • USRA will leverage its existing capabilities in partnership with both DHS OUP and MSRDC to implement this comprehensive new program.

Escient Pharmaceuticals Announces $120 Million Series C Financing

Retrieved on: 
Monday, November 28, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NEA, Skin, Tissue, Pain, AD, CSU, Gastrointestinal tract, Carma, OUP, Therapy, Cholestatic pruritus, MRGPRX4, Allergy, MRGPRX2, Atopic dermatitis, Pharmaceutical industry, Vaccine, Thakeham

Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing.

Key Points: 
  • Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $120 million Series C financing.
  • Proceeds from the financing will be used to advance the companys pipeline of two first-in-class product candidates in several indications.
  • Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders.
  • Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors.

Key Life Sciences Stakeholders Launch Representative Term Sheet

Retrieved on: 
Monday, November 28, 2022
Professional Services, Medical Devices, Health, Legal, Start-Up, General Health, University of Pennsylvania, RA, Third Rock Ventures, University, Johns Hopkins, Patient, University of Kentucky, Harvard University, MIT, Cornell University, Indiana University, Duke, Word, Stanford University, University of Michigan, OUP, Therapy, PDF, Hope, Andreessen Horowitz, Risk management, Private investigator, Yale University, New York University, Polaris, California Institute of Technology

The philosophical underpinnings can be found here: Term Sheet Recommendations for Launching University Life Science Startups and Recommended Process Improvements for Launching University Life Science Startups , initially released in December 2020.

Key Points: 
  • The philosophical underpinnings can be found here: Term Sheet Recommendations for Launching University Life Science Startups and Recommended Process Improvements for Launching University Life Science Startups , initially released in December 2020.
  • One important note: The creators use representative to describe the term sheet because the great majority of the terms would be considered reasonable by parties on both sides.
  • As a result, in many situations, the term sheet could be used without significant further edits.
  • Over the next few months, the creators hope to release a full license agreement template based on this term sheet.